Meet Dr. Robert Harman, Co-Founder and CEO of Personalized Stem Cells
Co-Founder and CEO of Personalized Stem Cells Inc., Dr. Robert Harman, has dedicated the majority of his career to developing stem cell therapy for humans and animals.
Stem Cell Therapy for Pain Management
Recent literature supports the notion that stem cells have the ability to directly modulate pain.
One Medicine: Animals Helping People
Nearly two decades’ worth of experience in the veterinary field led to the formation of Personalized Stem Cells, a human adipose-derived stem cell company.
Personalized Stem Cells Out-Licenses Allogeneic Stem Cell Program Including COVID-19 Therapy
Personalized Stem Cells announces licensing agreement for its allogeneic stem cell program including COVID-19 therapy.
Faith in Regenerative Medicine: Securing Funding During Uncertain Times
Personalized Stem Cells secured $2.5 million during a Series A round of financing in spite of the current economic crisis.
Personalized Stem Cells Joins the Fight Against COVID-19
When COVID-19 was declared a global pandemic, we at Personalized Stem Cells felt called to action to manufacture and provide potentially life-saving stem cell therapy to patients ill with COVID-19.
The Stem Cell Clinical Trial That Could: Overcoming COVID-19 Challenges
Personalized Stem Cells has completed enrollment of their first FDA approved stem cell clinical trial.
What is ‘Personalized’ about Personalized Stem Cells, Inc.?
Personalized Stem Cells, Inc. provides stem cell processing services to doctors for their patients who are participating in FDA approved clinical trials
Personalized Stem Cells: Our Drive to Legitimize Stem Cell Therapy
Personalized Stem Cells is committed to providing high-quality stem cell processing services, as well as excellent technical, clinical, and regulatory support to physicians, clinical investigators, and patients.
Personalized Stem Cells Receives FDA Approval to Treat COVID-19 Patients in Clinical Trial
Personalized Stem Cells (PSC) recently received FDA approval to treat COVID-19 patients with stem cells in an upcoming clinical trial.